MARKET

OPRX

OPRX

OPTIMIZERX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.05
+1.08
+4.51%
After Hours: 25.79 +0.74 +2.95% 17:03 11/25 EST
OPEN
24.07
PREV CLOSE
23.97
HIGH
25.61
LOW
23.72
VOLUME
149.46K
TURNOVER
--
52 WEEK HIGH
25.61
52 WEEK LOW
6.50
MARKET CAP
378.47M
P/E (TTM)
-65.9905
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
OptimizeRx Ranked Number 432 Fastest-Growing Company in North America on Deloittes 2020 Technology Fast 500
Attributes 217% Revenue Growth to Rapidly Expanding Digital Health PlatformROCHESTER, Mich., Nov. 18, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, has ranked 432 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America. OptimizeRx grew revenue 217% from 2016 to 2019. OptimizeRx CEO William Febbo credits the company’s innovative digital health solutions, expanding client base and dedicated team with the company’s 217% revenue growth. He stated: "It is an honor to be recognized by Deloitte as one of the nation’s fastest growing companies. Our team has worked tirelessly and vigorously to get the company to where it is today. The company’s strong growth is a testament to our mission in providing quality, affordable healthcare solutions to both patients and physicians, especially in this post COVID world. We are positioned very well to capitalize on our near-term growth opportunities as we continue to provide long-term value for our shareholders.”Paul Silverglate, vice chairman, Deloitte LLP and U.S. technology sector leader, commented: “For more than 25 years, we’ve been honoring companies that define the cutting edge and this year’s Technology Fast 500 list is proof positive that technology — from software and digital media platforms, to biotech — truly does permeate so many facets of our lives. We congratulate this year’s winners, especially during a time when innovation is needed more than ever to address the monumental challenges posed by the pandemic.”“Each year the Technology Fast 500 listing validates how important technology innovation is to our daily lives. It was interesting to see this year that while software companies continued to dominate, biotech companies rose to the top of the winners list for the first time, demonstrating that new categories of innovation are accelerating in the pursuit of making life easier, safer and more productive,” said Mohana Dissanayake, partner, Deloitte & Touche LLP, and industry leader for technology, media and telecommunications, within Deloitte’s audit and assurance practice. “We extend sincere congratulations to these well-deserved winners — who all embody a spirit of curiosity, and a never-ending commitment to making technology advancements possible.”OptimizeRx recently reported that its revenue for the third quarter of 2020 increased 110% to a record $10.5 million versus the same year-ago quarter. The result keeps the company on track for another year of record growth in an expanding addressable market. About Deloitte’s 2020 Technology Fast 500™ Now in its 26th year, Deloitte’s Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2016 to 2019.In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $US50,000, and current-year operating revenues of at least $US5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.About Deloitte Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.About OptimizeRx OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. OptimizeRx Contact  Doug Baker, CFO Tel (248) 651-6568 (x807) dbaker@optimizerx.com Media Contact Maira Alejandra, Media Relations Manager Tel (754) 245-7070 malejandra@optimizerx.comInvestor Relations Contact  Ron Both, CMA  Tel (949) 432-7557  oprx@cma.team
GlobeNewswire · 11/18 12:31
Point-of-Care Industry Expert, Angelo Campano, Joins OptimizeRx Executive Leadership as Senior Vice President and Principal of Agency Channels
Campano Brings More than 15 Years of Experience Leading Digital Channel Partnerships and InnovationROCHESTER, Mich., Nov. 11, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has appointed Angelo Campano to the new position of senior vice president and principal of agency channels. Campano will be responsible for driving the strategic growth and expansion of OptimizeRx partnerships with healthcare advertising agencies. This includes implementing point-of-care engagement programs designed for specific populations of patients and providers.“Angelo is an incredibly well-respected thought leader, innovator and strategist in point-of-care solutions, and we are honored to have him join our team,” said Steve Silvestro, chief commercial officer at OptimizeRx. “His proven ability to develop partnerships that bring digital touchpoints together at the point-of-care greatly complements our mission of helping life sciences be present throughout the care journey.“As we evolve our platform to meet the growing need for connectivity and even greater focus on specialty medications, Angelo’s expertise will help us drive even more growth and accelerate innovation in the collaboration between healthcare stakeholders.”The OptimizeRx digital health and communication platform connects the treatment support of life sciences to all stages of a patient’s care journey, and helps people afford and stay on medications through the doctor-recommended course of treatment.The company’s point-of-care expansions this year include partnerships with Change Healthcare and Epion. It has also added point-of-dispense touchpoints through a new partnership with Higi, which represents innovative new modes of delivery for healthcare advertising agencies who are looking to serve valuable support content on behalf of life science organizations. It has also added point-of-dispense touchpoints through a new partnership with Higi, which represents innovative new modes of delivery for healthcare advertising agencies who are looking to serve valuable support content on behalf of life science organizations.“I am excited to join the OptimizeRx team at this pivotal stage of the company’s growth and expansion at the point of care,” commented Campano. “I’ve spent my career deeply embedded in channel communications for life sciences, and I’ve witnessed OptimizeRx grow and innovate tremendously. It is a natural step for me to build on the work I’ve done connecting siloed pockets of healthcare providers and enabling more effective distribution of life sciences support.”Campano has been a trailblazer in innovation and leadership in electronic health record (EHR) workflow and hub services. Prior to joining OptimizeRx, he served as senior vice president for point of care marketing at Ogilvy Health, where he created a proprietary business rules engine that enables specific interactions across multiple EHR platforms and eliminates the fragmentation of healthcare provider reach. He has established partnerships with more than 245 EHR platforms, 100 specialty pharma partners and five communications partners to bring life sciences resources to more places at the point-of-care.Campano received a bachelor’s degree in bioinformatics from Rutgers University. He was inducted into the Medical Advertising Hall of Fame in 2014 as a Future Hall of Famer, and was the recipient of the PM360’s ELITE Innovator Award in 2017.About OptimizeRx OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.OptimizeRx Contact  Doug Baker, CFO Tel (248) 651-6568 (x807) dbaker@optimizerx.com Media Relations Contact  Maira Alejandra, Media Relations Manager Tel (754) 245-7070  malejandra@optimizerx.com Investor Relations Contact  Ron Both, CMA  Tel (949) 432-7557  oprx@cma.team
GlobeNewswire · 11/11 12:31
OptimizeRx: Q3 Earnings Insights
Shares of OptimizeRx (NASDAQ:OPRX) were flat in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share rose 240.00% over the past year to $0.07, which beat the estimate of $0.04.Revenue of $10,519,000 rose by 110.25% year over year, which beat the estimate of $9,770,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: Nov 09, 2020View more earnings on OPRXTime: 04:30 PMET Webcast URL: https://investors.optimizerx.com/events/event-details/oprx-3rd-quarter-2020-earnings-conference-callPrice Action Company's 52-week high was at $22.55Company's 52-week low was at $6.50Price action over last quarter: Up 23.90%Company Overview OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.See more from Benzinga * Click here for options trades from Benzinga * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/09 21:45
OptimizeRx Q3 Adj. EPS $0.07 Beats $0.04 Estimate, Sales $10.50M Beat $9.77M Estimate
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.04 by 75 percent. This is a 240 percent increase over losses of $(0.05) per share from the same
Benzinga · 11/09 21:04
OptimizeRx EPS beats by $0.03, beats on revenue
OptimizeRx (OPRX): Q3 Non-GAAP EPS of $0.07 beats by $0.03; GAAP EPS of -$0.02 beats by $0.02.Revenue of $10.52M (+110.4% Y/Y) beats by $0.75M.Press Release
Seekingalpha · 11/09 21:03
OptimizeRx Third Quarter 2020 Revenue Up 110% to Record $10.5 Million, Driving Non-GAAP Net Income of $1.1 million or $0.07 Per Share
ROCHESTER, Mich., Nov. 09, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, reported results for the three and nine months ended September 30, 2020. Quarterly and nine months comparisons are to the same year-ago period. Financial Highlights * Revenue in the third quarter of 2020 increased 110% to a record $10.5 million, with the first nine months of 2020 up 56% to a record $26.9 million. * Gross profit in the third quarter of 2020 increased 99% to $6.0 million. * GAAP net loss totaled $0.3 million or $(0.02) per share in the third quarter, with non-GAAP net income at $1.1 million or $0.07 per share (see definition of this non-GAAP measure and reconciliation to GAAP, below). * Cash and cash equivalents totaled $12.0 million at September 30, 2020. * Closed additional enterprise deals, bringing total value of enterprise-level engagements to $21 million in annualized revenue. Q3 2020 Operational Highlights * Expanded direct-to-patient reach via partnership with Epion Health, a leader in digital patient engagement solutions, allowing patients at health systems and medical groups across the nation access to the OptimizeRx digital health and communications platform. * Partnered with Higi, a consumer healthcare technology and engagement company, to provide healthcare consumers with financial assistance and treatment support programs at point-of-dispense. Higi provides OptimizeRx access to more than 10,000 self-service health stations nationwide that allow consumers to measure, track and act on their health data. * Expanded digital health communication network in collaboration with Change Healthcare to enable providers in the Change Healthcare network to digitally receive important information from the life sciences industry via OptimizeRx. * Secured two SaaS-based enterprise-level engagements with a combined annual contract value of $3.6 million. * Enhanced corporate governance with the addition of Greg Wasson, former president and CEO of Walgreens Boots Alliance, to the board of directors. * Continued webinar series featuring industry thought leaders discussing innovative ideas for improving medication launches.Q3 2020 Financial SummaryTotal revenue in the third quarter of 2020 increased 110% to a record $10.5 million versus $5.0 million in the same year-ago quarter. The quarterly increase was due to increases in sales in the company’s messaging products and patient engagement products, including from its acquisition of RMDY Health in 2019.Gross margin decreased to 57.1% in the third quarter of 2020 as compared to 60.4% in the year-ago quarter. The decrease was related to a change in mix of services provided. The company expects gross margin to improve in the fourth quarter with a target of 60% for the year.Operating expenses totaled $6.2 million, up from $5.0 million in the same year-ago quarter. The increase was due to the company’s efforts to expand its product line and build out its organization for future growth.Net loss on a GAAP basis in the third quarter of 2020 was $0.3 million or $(0.02) per share, as compared to a net loss of $1.6 million or $(0.11) per share in the third quarter of 2019.Non-GAAP net income for the third quarter of 2020 was $1.1 million or $0.07 per share, compared to non-GAAP net loss of $0.9 million or $(0.07) per diluted share in the same year-ago period (see definition of these non-GAAP measures and reconciliation to GAAP, below).While the company expects to return to GAAP profitability as its revenue grows, expenses related to investments in growth initiatives or non-cash charges could result in a GAAP loss in any given quarter. Given the opportunity at hand as discussed below, the company continues to be focused on top-line growth while maintaining a strong balance sheet.  Cash and cash equivalents totaled $12.0 million at September 30, 2020, as compared to $14.1 million at June 30, 2020. The decrease was due to an increased investment in working capital. The company has continued to operate debt-free and expects to be cash-flow positive for the remainder of the year.Management Commentary“In Q3, we realized triple digit revenue growth, mostly organic, which drove strong non-GAAP net income,” stated OptimizeRx CEO, William Febbo. “It reflects how our pharma clients are increasingly seeing the point-of-care as essential to their marketing spend.”“We also continued to see a growing proportion of enterprise-level recurring revenue and growing interest from our customer base for our new solutions, such as patient engagement, hub enrollment and TelaRep™. We finalized our integration and go-forward plan for patient engagement, which provides additional scale for driving growth in recurring revenue. It also opens up access to additional budgets within our client base and supports improved gross margins over time.“We expanded our platform reach during the quarter via our Higi and Epion partnerships that connect us digitally to millions of new patients. We see ourselves at just the beginning of a broad expansion into retail or point-of-dispense as another channel to enable affordability and adherence. Both of these partnerships are very timely, as we are all looking for ways to connect digitally at more points in the healthcare workflow and maximize access to care. “We are seeing more rapid adoption of digital tools for doctors to combat the COVID disruption. Macro trends are in our favor as highlighted by the rapid adoption of telehealth and other digital tools. A clear theme forming is the need for the appropriate digital tools for doctors to maintain their practices with under such drastic disruptions occurring with the pandemic. This allows for our solutions to be highlighted as an effective tool set to help deliver care to patients. “Looking ahead, we are on track for a strong annual growth rate, non-GAAP income and positive cash flow from operational activities. Our pipeline is better than it has ever been, currently sitting at $140 million, nearly double versus this time last year. We continue to anticipate a close rate in the range of 35 percent to 50 percent, with these prospects keeping us on pace for another year of record growth in an expanding addressable market.”Conference CallOptimizeRx management will host the presentation, followed by a question and answer period.Date: Monday, November 9, 2020 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Toll-free dial-in number: 1-800-430-8332 International dial-in number: 1-323-347-3277 Conference ID: 9818386Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.A replay of the call will be available after 7:30 p.m. Eastern time on the same day through November 30, 2020, as well as available for replay via the Investors section of the OptimizeRx website at optimizerx.com/investors.Toll-free replay number: 1-844-512-2921 International replay number: 1-412-317-6671 Replay ID: 9818386Definition and Use of Non-GAAP Financial Measures This earnings release includes a presentation of non-GAAP net income (loss) and non-GAAP earnings (loss) per share or non-GAAP EPS, both of which are non-GAAP financial measures.The company defines non-GAAP net income (loss) as GAAP net income (loss) with an adjustment to add back depreciation, amortization, non-cash lease expense, stock-based compensation, acquisition expenses, income or loss related to the fair value of contingent consideration, and deferred income taxes. Non-GAAP EPS is defined as non-GAAP net income (loss) divided by the number of weighted average shares outstanding on a basic and diluted basis. The company has provided non-GAAP financial measures to aid investors in better understanding its performance. Management believes that these non-GAAP financial measures provide additional insight into the operations and cashflow of the company.Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash operating expenses, management believes that providing non-GAAP financial measures that excludes non-cash expenses allows for meaningful comparisons between the company’s core business operating results and those of other companies, as well as provides an important tool for financial and operational decision making and for evaluating the company’s own core business operating results over different periods of time.The company’s non-GAAP net income (loss) and non-GAAP EPS measures may not provide information that is directly comparable to that provided by other companies in the company’s industry, as other companies in the industry may calculate such non-GAAP financial results differently. The company’s non-GAAP net income (loss) and non-GAAP EPS are not measurements of financial performance under GAAP and should not be considered as an alternative to operating income or as an indication of operating performance or any other measure of performance derived in accordance with GAAP. The company does not consider these non-GAAP measures to be substitutes for or superior to the information provided by its GAAP financial results.The table, “Reconciliation of non-GAAP to GAAP Financial Measures,” included below, provides a reconciliation of non-GAAP net income (loss) and non-GAAP EPS for the three months and nine months ended September 30, 2020 and 2019.About OptimizeRx OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that facilitates communication at the point-of-care among all stakeholders in healthcare. Primarily focused on life science and payer clients, its suite of digital and mobile SaaS-based solutions enables affordability, patient adherence and care management. OptimizeRx’s network reaches more than 60% of U.S. ambulatory providers, delivering therapeutic support on specialty medications and patient financial assistance directly within a provider’s workflow through leading electronic health platforms. OptimizeRx’s fully integrated platform supports the real-time exchange of information, improving provider knowledge and patient engagement, and ultimately leading to healthier outcomes. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.Company Contact Doug Baker, CFO Tel (248) 651-6568 x807 dbaker@optimizerx.comMedia Contact Maira Alejandra, Media Relations Manager Tel (754) 245-7070 malejandra@optimizerx.comInvestor Relations Contact Ron Both or Grant Stude CMA Investor Relations Tel (949) 432-7557 oprx@cma.teamOPTIMIZERx CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)    September 30, 2020  December 31, 2019         ASSETS      Current Assets        Cash and cash equivalents$12,032,538  $18,852,680  Accounts receivable, net 13,332,552   7,418,025  Prepaid expenses 1,867,590   871,043  Total Current Assets 27,232,680   27,141,748  Property and equipment, net 151,809   176,014  Other Assets        Goodwill 14,740,031   14,740,031  Technology assets, net 5,464,916   6,238,453  Patent rights, net 2,388,320   2,550,587  Other intangible assets, net 4,677,439   5,151,102  Right of use assets, net 474,906   559,863  Other assets and deposits 16,013   80,727  Total Other Assets 27,761,625   29,320,763  TOTAL ASSETS$55,146,114  $56,638,525           LIABILITIES AND STOCKHOLDERS’ EQUITY        Current Liabilities        Accounts payable – trade$480,502  $492,995  Accrued expenses 1,794,019   1,800,635  Revenue share payable 3,642,088   1,618,438  Current portion of lease obligations 121,583   115.431  Current portion of contingent purchase price payable 1,610,813   1,500,000  Deferred revenue 461,277   580,014  Total Current Liabilities 8,110,282   6,107,513  Non-current Liabilities        Lease obligations, net of current portion 356,618   448,753  Contingent purchase price payable, net of current portion -   5,220,000  Total Non-current Liabilities 356,618   5,668,753  Total Liabilities 8,466,900   11,776,266  Commitments and contingencies -   -  Stockholders’ Equity        Preferred stock, $0.001 par value, 10,000,000 shares authorized, no issued and outstanding at September 30, 2020 or December 31, 2019 -   -  Common stock, $0.001 par value, 500,000,000 shares authorized, 15,072,226 and 14,600,579 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively 15,072   14,601  Additional paid-in-capital 83,653,045   78,272,268  Accumulated deficit (36,988,903)  (33,424,610) Total Stockholders’ Equity 46,679,214   44,862,259  TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$55,146,114  $56,638,525           OPTIMIZERx CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)   For the Three Months Ended  For the Nine Months Ended   September 30,  September 30,   2020  2019  2020  2019               NET REVENUE$10,519,191  $5,002,767  $26,887,022  $17,218,492  COST OF REVENUES 4,504,844   1,981,143   11,385,622   6,251,766  GROSS MARGIN 6,014,347   3,021,624   15,501,400   10,966,726                   OPERATING EXPENSES 6,191,069   5,008,934   18,993,187   12,341,827  LOSS FROM OPERATIONS (176,722)  (1,987,310)  (3,491,787)  (1,375,101)                  OTHER INCOME (EXPENSE)                Interest income 4,218   136,368   67,884   192,305  Change in fair value of contingent consideration (110,390)  280,000   (140,390)  25,000                   TOTAL OTHER INCOME (EXPENSE) (106,172)  416,368   (72,506)  217,305                   LOSS BEFORE PROVISION FOR INCOME TAXES (282,894)  (1,570,942)  (3,564,293)  (1,157,796)                  PROVISION FOR INCOME TAXES -   -   -   -  NET INCOME (LOSS)$(282,894) $(1,570,942) $(3,564,293) $(1,157,796)                  WEIGHTED AVERAGE SHARES OUTSTANDING                BASIC 14,900,971   14,146,489   14,726,534   12,996,590  DILUTED 14,900,971   14,146,489   14,726,534   12,996,590                   EARNINGS (LOSS) PER SHARE                BASIC$(0.02) $(0.11) $(0.24) $(0.09) DILUTED$(0.02) $(0.11) $(0.24) $(0.09)                  OPTIMIZERx CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) For the Nine Months Ended September 30,   2020  2019  CASH FLOWS FROM OPERATING ACTIVITIES:      Net Loss$(3,564,293) $(1,157,796) Adjustments to reconcile net loss to net cash used in operating activities:        Depreciation, amortization, and non-cash lease expense 1,563,883   745,928  Stock-based compensation 2,066,609   1,407,938  Stock issued as board compensation 325,011   361,782  Provision for loss on accounts receivable 80,000   -  Change in fair value of contingent consideration 140,390   (25,000) Changes in:        Accounts receivable (5,994,527)  (700,549) Prepaid expenses and other assets (931,833)  (469,623) Accounts payable (12,493)  184,464  Revenue share payable 2,023,650   (240,329) Accrued expenses and other liabilities 704,599   (772,953) Deferred revenue (118,737)  505,279  NET CASH USED IN OPERATING ACTIVITIES (3,717,781)  (160,859)          CASH FLOWS FROM INVESTING ACTIVITIES:        Purchase of equipment (45,254)  (61,457) Purchase of intangible assets -   (1,000,000) NET CASH USED IN INVESTING ACTIVITIES (45,254)  (1,061,457)          CASH FLOWS FROM FINANCING ACTIVITIES:        Proceeds from issuance of common stock, net of commission costs 1,332,080   22,369,960  Expenses related to issuance cost of common stock -   (301,711) Payment of contingent consideration (4,389,187)  -  NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (3,057,107)  22,068,249  NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (6,820,142)  20,845,933  CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD 18,852,680   8,914,034  CASH AND CASH EQUIVALENTS – END OF PERIOD$12,032,538  $29,759,967           SUPPLEMENTAL CASH FLOW INFORMATION:        Cash paid for interest$-  $-  Cash paid for income taxes$-  $-  Intangible asset additions included in accounts payable$-  $500,000  Acquisition liabilities paid in common stock$1,550,000  $-  Non-cash effect of cumulative adjustments to accumulated deficit$-  $3,229  Lease liabilities arising from right of use assets$-  $672,809           OPTIMIZERx CORPORATION Reconciliation of non-GAAP to GAAP Financial Measures (Unaudited) For the Three Months Ended September 30, For the Nine Months Ended September 30,   2020   2019   2020   2019  Net loss$(282,894) $(1,570,942) $(3,564,293) $(1,157,796) Depreciation, amortization, and non-cash lease expense 523,420   320,055   1,563,883   745,928  Stock-based compensation 756,437   590,244   2,391,619   1,769,720  Income or loss related to the fair value of contingent consideration 110,390   (280,000)  140,390   (25,000) Non-GAAP net income (loss)$1,107,353  $(940,643) $531,599  $1,332,852           Non-GAAP net income (loss) per share        Basic$0.07  $(0.07) $0.04  $0.10  Diluted$0.07  $(0.07) $0.03  $0.10  Weighted average shares outstanding:        Basic 14,900,971   14,146,489   14,726,534   12,996,590  Diluted 15,996,241   14,146,489   15,640,050   13,952,330
GlobeNewswire · 11/09 21:01
OptimizeRx Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 9, 2020 / OptimizeRx Corp.
ACCESSWIRE · 11/09 19:30
OptimizeRx (NASDAQ:OPRX) Shareholders Have Enjoyed A Whopping 463% Share Price Gain
For us, stock picking is in large part the hunt for the truly magnificent stocks. Mistakes are inevitable, but a...
Simply Wall St. · 10/27 15:22
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OPRX. Analyze the recent business situations of OPTIMIZERX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OPRX stock price target is 33.33 with a high estimate of 40.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 95
Institutional Holdings: 10.97M
% Owned: 72.58%
Shares Outstanding: 15.11M
TypeInstitutionsShares
Increased
15
421.79K
New
23
806.84K
Decreased
26
435.21K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Software
+2.24%
Software & IT Services
+0.82%
Key Executives
Chairman/Director
Gus Halas
President
Miriam Paramore
Chief Executive Officer/Director
William Febbo
Chief Financial Officer
Douglas Baker
Senior Vice President
Angelo Campano
Chief Technology Officer
Todd Inman
Other
Stephen Silvestro
Director
Gregory Wasson
Independent Director
James Lang
Independent Director
Patrick Spangler
Independent Director
Lynn Vos
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OPRX
OptimizeRx Corporation is a digital health company that facilitates communication at point-of-care among stakeholders in healthcare. The Company provides electronic clinical information through electronic health records (EHRs) to the medical profession, providing a direct channel for pharmaceutical companies to communicate with healthcare providers. Primarily focused on life science and payer clients, its suite of digital and mobile software as a service (SaaS)-based solutions enables affordability, patient adherence and care management. The Company’s products and applications include financial messaging, brand and clinical messaging, brand support, patient engagement and digital therapeutics. Its integrated financial messaging platform is a virtual patient support center that allows doctors and staff to access a universe of sample vouchers, co-pay coupons and other patient support through their electronic medical record (EMR) and/or e-Prescribe systems.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of OptimizeRx Corporation stock information, including NASDAQ:OPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPRX stock methods without spending real money on the virtual paper trading platform.